Role of Serum Pepsinogen II and Helicobacter pylori Status in the Detection of Diffuse-Type Early Gastric Cancer in Young Individuals in South Korea
2
조회
0
다운로드
11
인용
0
참고문헌
키워드
초록
Background/Aims: The utility of serum pepsinogen (sPG) I and the sPGI/II ratio as biomarkers for screening individuals with gastric cancer (GC) has not been established in Korea. The aim of this study was to define the role of sPG, especially sPGII, in GC screening. Methods: This study enrolled 2,940 subjects, including patients with GC (n=1,124) or gastric dysplasia (n=353) and controls (n=1,463). Tests to determine sPG levels and Helicobacter pylori (HP) infection status were performed. Area under the curve and receiver operating characteristic curve were calculated to identify the optimal cutoff values for sPG. The usefulness of sPG levels for the detection of GC and gastric dysplasia was validated by multivariate logistic regression. Results: The sPGI/II ratio was associated with the risk of gastric dysplasia and advanced-stage intestinal-type GC (IGC). In contrast, sPGII was associated with the risk of early-stage diffuse-type GC (DGC). Significantly higher risk was indicated by an sPGI/II ratio <3 for gastric dysplasia and advanced-stage IGC and by sPGII levels ≥20 µg/L for early-stage DGC. Positive HP status showed a stronger association with DGC than with IGC. When sPGII level and HP status were combined, the prevalence of DGC was higher in the ≥20 µg/L sPGII and HP-positive group. Age younger than 40 years was strongly related to early-stage DGC, especially in females (odds ratio, 21.00; p=0.006). Conclusions: sPGII ≥20 ng/mL and positive HP status suggest a risk of early-stage DGC, particularly in young adult females in South Korea.
Abstract
Background/Aims: The utility of serum pepsinogen (sPG) I and the sPGI/II ratio as biomarkers for screening individuals with gastric cancer (GC) has not been established in Korea. The aim of this study was to define the role of sPG, especially sPGII, in GC screening. Methods: This study enrolled 2,940 subjects, including patients with GC (n=1,124) or gastric dysplasia (n=353) and controls (n=1,463). Tests to determine sPG levels and Helicobacter pylori (HP) infection status were performed. Area under the curve and receiver operating characteristic curve were calculated to identify the optimal cutoff values for sPG. The usefulness of sPG levels for the detection of GC and gastric dysplasia was validated by multivariate logistic regression. Results: The sPGI/II ratio was associated with the risk of gastric dysplasia and advanced-stage intestinal-type GC (IGC). In contrast, sPGII was associated with the risk of early-stage diffuse-type GC (DGC). Significantly higher risk was indicated by an sPGI/II ratio <3 for gastric dysplasia and advanced-stage IGC and by sPGII levels ≥20 µg/L for early-stage DGC. Positive HP status showed a stronger association with DGC than with IGC. When sPGII level and HP status were combined, the prevalence of DGC was higher in the ≥20 µg/L sPGII and HP-positive group. Age younger than 40 years was strongly related to early-stage DGC, especially in females (odds ratio, 21.00; p=0.006). Conclusions: sPGII ≥20 ng/mL and positive HP status suggest a risk of early-stage DGC, particularly in young adult females in South Korea.
참고문헌 (51)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Jun JK, "Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality", Gastroenterology, 152, pp.1319~1328 (2017)
- Samloff IM, "Pepsinogens, pepsins, and pepsin inhibitors", Gastroenterology, 60, pp.586~604 (1971)
- Kodoi A, "Serum pepsinogen in screening for gastric cancer", J Gastroenterol, 30, pp.452~460 (1995)
- Samloff IM, "Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology : a study in relatives of patients with pernicious anemia", Gastroenterology, 83, pp.204~209 (1982)
- Uemura N, "Helicobacter pylori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)
- Yun CY, "Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors", Helicobacter, 23, pp.e12542~ (2018)
- Kang JM, "The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea", Helicobacter, 13, pp.146~156 (2008)
- Kikuchi S, "Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults", Cancer, 73, pp.2695~2702 (1994)
- Yanaoka K, "Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels", Int J Cancer, 123, pp.917~926 (2008)
- Ito M, "Serum screening for detection of high-risk group for early-stage diffuse type gastric cancer in Japanese", J Gastroenterol Hepatol, 27, pp.598~602 (2012)
- Lauren P, "The two histological main types of gastric carcinoma : diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
- Dixon MF, "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994", Am J Surg Pathol, 20, pp.1161~1181 (1996)
- Loffeld RJ, "Helicobacter pylori in gastric biopsy specimens : comparison of culture, modified Giemsa stain, and immunohistochemistry. A retrospective study", J Pathol, 165, pp.69~73 (1991)
- Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection", Am J Gastroenterol, 102, pp.1808~1825 (2007)
- Lee JY, "Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance", Dig Dis Sci, 59, pp.1235~1243 (2014)
- Plebani M, "Helicobacter pylori serology in patients with chronic gastritis", Am J Gastroenterol, 91, pp.954~958 (1996)
- Mårdh E, "Diagnosis of gastritis by means of a combination of serological analyses", Clin Chim Acta, 320, pp.17~27 (2002)
- Pilotto A, "Cure of Helicobacter pylori infection in the elderly : effects of eradication on gastritis and serological markers", Aliment Pharmacol Ther, 10, pp.1021~1027 (1996)
- Kawai T, "Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan", Inflammopharmacology, 15, pp.31~35 (2007)
- Ning PF, "Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and Helicobacter pylori associated gastric diseases", World J Gastroenterol, 11, pp.2545~2548 (2005)
- Sipponen P, "Helicobacter pylori infection and chronic gastritis in gastric cancer", J Clin Pathol, 45, pp.319~323 (1992)
- Nardone G, "Review article : Helicobacter pylori and molecular events in precancerous gastric lesions", Aliment Pharmacol Ther, 20, pp.261~270 (2004)
- Correa P, "Precursors of gastric and esophageal cancer", Cancer, 50, pp.2554~2565 (1982)
- Laurén P, "Histogenesis of intestinal and diffuse types of gastric carcinoma", Scand J Gastroenterol Suppl, 180, pp.160~164 (1991)
- Correa P, "Human gastric carcinogenesis : a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention", Cancer Res, 52, pp.6735~6740 (1992)
- Correa P, "Carcinogenesis of Helicobacter pylori", Gastroenterology, 133, pp.659~672 (2007)
- Vauhkonen M, "Pathology and molecular biology of gastric cancer", Best Pract Res Clin Gastroenterol, 20, pp.651~674 (2006)
- Yanaoka K, "Cancer high-risk subjects identified by serum pepsinogen tests : outcomes after 10-year follow-up in asymptomatic middle-aged males", Cancer Epidemiol Biomarkers Prev, 17, pp.838~845 (2008)
- Ohata H, "Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography", Cancer Sci, 96, pp.713~720 (2005)
- Correa P, "Does Helicobacter pylori cause gastric cancer via oxidative stress", Biol Chem, 387, pp.361~364 (2006)
- Kang GH, "Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis", Lab Invest, 83, pp.635~641 (2003)
- Chan AO, "Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer", Gut, 52, pp.502~506 (2003)
- Maekita T, "High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk", Clin Cancer Res, 12, pp.989~995 (2006)
- Tamura G, "E-cadherin gene promoter hypermethylation in primary human gastric carcinomas", J Natl Cancer Inst, 92, pp.569~573 (2000)
- Kuwahara Y, "Relationship between serologically diagnosed chronic atrophic gastritis, Helicobacter pylori, and environmental factors in Japanese men", Scand J Gastroenterol, 35, pp.476~481 (2000)
- Backert S, "Functional analysis of the cag pathogenicity island in Helicobacter pylori isolates from patients with gastritis, peptic ulcer, and gastric cancer", Infect Immun, 72, pp.1043~1056 (2004)
- Kuniyasu H, "Helicobactor pylori infection is closely associated with telomere reduction in gastric mucosa", Oncology, 65, pp.275~282 (2003)
- Wang L, "Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8", A9 proinflammatory proteins, 2013, pp.190, 794~804
- Stemmermann GN, "The relation of pepsinogen group II(PGII)expression to intestinal metaplasia and gastric cancer", Histopathology, 49, pp.45~51 (2006)
- Bedikian AY, "Gastric carcinoma in young adults", South Med J, 72, pp.654~656 (1979)
- Isobe T, "Characteristics and prognosis of gastric cancer in young patients", Oncol Rep, 30, pp.43~49 (2013)
- Yoshihara M, "Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects", Am J Gastroenterol, 93, pp.1090~1096 (1998)
- Miki K, "Gastric cancer screening using the serum pepsinogen test method", Gastric Cancer, 9, pp.245~253 (2006)
- Kitahara F, "Accuracy of screening for gastric cancer using serum pepsinogen concentrations", Gut, 44, pp.693~697 (1999)
- Dinis-Ribeiro M, "Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening", J Med Screen, 11, pp.141~147 (2004)
- Hattori Y, "Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens", Jpn J Cancer Res, 86, pp.1210~1215 (1995)
- Oishi Y, "The serum pepsinogen test as a predictor of gastric cancer : the Hisayama study", Am J Epidemiol, 163, pp.629~637 (2006)
- Ohata H, "Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer", Int J Cancer, 109, pp.138~143 (2004)
- Watabe H, "Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status : a prospective endoscopic cohort study", Gut, 54, pp.764~768 (2005)
- Lee JY, "Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer", Clin Exp Med, 17, pp.403~410 (2017)